How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

calendar_today April 27, 2026 person domain abbvie

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn’s disease patients will have an additional option for induction of risankizumab-rzaa which is already…

open_in_new Read original post